Pharmaceuticals, Biotechnology and Life Sciences
Gilead Sciences has announced data from two Phase 3 studies evaluating the safety and efficacy of Genvoya for the treatment of HIV-1 infection in treatment-naïve adults.
“The rapid roll-out of our nationwide ambulatory clinic model, and our significant new participation in the Georgian pharmaceuticals market will continue to create further business development and cost efficiency opportunities over the next few years,” said the group’s CEO Nikoloz Gamkrelidze.
Navamedic, Norwegian medtech and pharmaceutical products company, has reported Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) of €0,6 million which represents small increase comparing to same period last year when company’s EBITDA was slightly under zero.
Pharmapack Europe – organised by UBM EMEA – closed its 2017 edition, marking 20 years of its presence, as a major European event for pharmaceutical packaging and drug delivery devices. The top trends that emerged from the two-day event included: patient centricity, traceability, innovation, compliance and adherence.
As a part of Clintec’s – a privately-owned full-service Clinical Research Organisation (CRO) – 20th anninversary and reaching certain milestones after another year of growth, Clintec on Wednesday launched its new brand identity reflected in their newly created website.
At least 13 people were killed and 85 injured when a suicide bomber struck Monday evening around 6pm outside the Punjab Assembly in Lahore during a protest, reported Pakistani Dawn citing police officials.
Moberg Pharma has posted net profit after tax of SEK 32.7 million (€3.45 million) which is up from SEK 25.5 million last year.
Probi AB has appointed Jörn Andreas as CFO. Andreas will replace Niklas Brandt who will remain in Probis leadership team as CIO with responsibility for IT infrastructure and Investor relations.
The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry.
Turbulent several months for Teva in which it saw many challenges and achievements saw the company loosing its CEO, several trials in the USA, one of which being for bribery, and patent related trials that Teva filed, and was filed against.